<DOC>
	<DOCNO>NCT00223899</DOCNO>
	<brief_summary>To evaluate safety intratumorally inject VCL-IM01 dos 0.5 mg ( 1 tumor ) , 1.5 mg ( 1 tumor ) , 5 mg ( 1 tumor ) , 10 mg ( 2 tumor , 5 mg per tumor ) 15 mg ( 3 tumor , 5 mg per tumor ) follow electroporation .</brief_summary>
	<brief_title>A Trial Evaluate Safety Intratumoral VCL-IM01 Followed Electroporation Metastatic Melanoma</brief_title>
	<detailed_description>Eligible subject receive intratumoral injection VCL-IM01 follow electroporation inject tumor ( ) . Subjects enrol receive one course treatment . A course treatment two cycle , cycle consist four weekly injection/electroporation administration follow observation period two week . Subjects ' tumor evaluate Screening , end Cycle 2 , six month ( Week 26 ) initial drug administration .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>Inclusion Criteria Key criterion include : Confirmed recurrent metastatic melanoma Tumor ( ) treat must least 1 cm 1 cm , accessible treatment Able carry normal daily activity light work without assistance Not currently receive chemotherapy immunotherapy Normal blood chemistry blood cell count ( elevation LDH le equal 1.5 time normal allow ) Able willing give inform consent . Exclusion Criteria Key criterion include : History brain tumor ( resect stereotactically treat allow ) History liver tumor Subjects whose melanoma cure surgery Pregnant Subjects electronic pacemaker , defibrillator , implant electronic device .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Melanoma</keyword>
	<keyword>Electroporation</keyword>
	<keyword>IL-2</keyword>
</DOC>